Arteriosclerosis and Thrombosis, Vol 11, 1295-1302, Copyright © 1991 by American Heart Association

ARTICLES

Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice

T Hayek, T Chajek-Shaul, A Walsh, N Azrolan and JL Breslow
Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York, NY 10021-6399.

Probucol effects on lipoprotein metabolism were determined in control and human apolipoprotein A-I transgenic (HuAITg) mice. In control mice, probucol reduced total cholesterol from 67 +/- 2 to 25 +/- 2 mg/dl by reducing high density lipoprotein (HDL) cholesterol from 46 +/- 20 to 14 +/- 1 mg/dl and low density lipoprotein (LDL) cholesterol from 11 +/- 1 to 5 +/- 1 mg/dl. Apolipoprotein (apo) A-I levels were reduced from 122 +/- 8 to 56 +/- 5 mg/dl. In HuAITg mice, probucol reduced total cholesterol from 121 +/- 5 to 77 +/- 3 mg/dl by reducing HDL cholesterol from 84 +/- 4 to 56 +/- 3 mg/dl and LDL cholesterol from 19 +/- 2 to 11 +/- 2 mg/dl. Human apo A-I levels were reduced from 267 +/- 13 to 144 +/- 12 mg/dl and mouse apo A-I levels from 18 +/- 2 to 9 +/- 2 mg/dl. Control animals have primarily a monodisperse HDL with a particle diameter of 10 nm. Probucol did not appear to change the particle size distribution in the control animals. The HuAITg mice have a polydisperse HDL with particle diameters of 10.1 and 8.5 nm. Probucol treatment of these animals resulted in HDL with particle diameters of 9.4 and 8.5 nm, apparently reducing the size of the larger particles. In vivo turnover studies revealed that the reduction in apo A-I was primarily due to a decrease in transport rate, whereas the reduction in HDL cholesterol was primarily due to an increase in HDL cholesteryl ester fractional catabolic rate.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				B. Asztalos, M. Lefevre, L. Wong, T. A. Foster, R. Tulley, M. Windhauser, W. Zhang, and P. S. Roheim Differential response to low-fat diet between low and normal HDL-cholesterol subjects J. Lipid Res., March 1, 2000; 41(3): 321 - 328. [Abstract] [Full Text]

				F. Rinninger, N. Wang, R. Ramakrishnan, X. C. Jiang, and A. R. Tall Probucol Enhances Selective Uptake of HDL-Associated Cholesteryl Esters In Vitro by a Scavenger Receptor B-I–Dependent Mechanism Arterioscler Thromb Vasc Biol, May 1, 1999; 19(5): 1325 - 1332. [Abstract] [Full Text] [PDF]

				M. H. Moghadasian, B. M. McManus, D. V. Godin, B. Rodrigues, and J. J. Frohlich Proatherogenic and Antiatherogenic Effects of Probucol and Phytosterols in Apolipoprotein E–Deficient Mice : Possible Mechanisms of Action Circulation, April 6, 1999; 99(13): 1733 - 1739. [Abstract] [Full Text] [PDF]

				D. A. Bird, R. K. Tangirala, J. Fruebis, D. Steinberg, J. L. Witztum, and W. Palinski Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice J. Lipid Res., May 1, 1998; 39(5): 1079 - 1090. [Abstract] [Full Text] [PDF]

				S. Levak-Frank, P. H. Weinstock, T. Hayek, R. Verdery, W. Hofmann, R. Ramakrishnan, W. Sattler, J. L. Breslow, and R. Zechner Induced Mutant Mice Expressing Lipoprotein Lipase Exclusively in Muscle Have Subnormal Triglycerides yet Reduced High Density Lipoprotein Cholesterol Levels in Plasma J. Biol. Chem., July 4, 1997; 272(27): 17182 - 17190. [Abstract] [Full Text] [PDF]

				R. K. Tangirala, F. Casanada, E. Miller, J. L. Witztum, D. Steinberg, and W. Palinski Effect of the Antioxidant N,N'-Diphenyl 1,4-Phenylenediamine (DPPD) on Atherosclerosis in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, October 1, 1995; 15(10): 1625 - 1630. [Abstract] [Full Text]